K Health | $50,000,000 | (Jul 2, 2024)
Pieces for Developers | $13,500,000 | (Jul 2, 2024)
Vitarka Therapeutics
United Kingdom
- London
- 12/04/2023
- Unknown
- $1,580,000
Curing the untreated: Vitarka Therapeutics is a pre-clinical biotech company determined to combat late-stage cancers.
- Industry Biotechnology Research
- Website https://www.vitarka.co.uk/
- LinkedIn https://www.linkedin.com/company/vitarka-therapeutics/
Related People
Vineeta TripathiFounder
United Kingdom -
London, England
15+ years’ in Pharmaceutical drug development for biologics within Neuroscience, Immuno-Oncology and Ophthalmology, project management, target product profile, go-to market strategy. Co-founded Vitarka Therapeutics, currently fundraising Seed investment round. Academic expertise in discovery and validation of TDP-43 mutations causing Motor Neuron Disease. Proven track record of publications in journals such as Science and Nature; total citation score of >7000. Co-inventor on patents for chimeric neurotoxin NMEs and therapeutic antibodies. Delivered 2 candidates to clinic for wet AMD. Won 3rd place for the 1st Roche pRED Oncology Award for innovative scientific achievements in “Novel highly tumor-selective membrane targets for antibody-based cancer therapy”.
Supercede | The Reinsurance Platform | $15,000,000 | (Jun 28, 2024)
illumex | $13,000,000 | (Jun 28, 2024)
AuthZed | $12,000,000 | (Jun 28, 2024)
Smartworks | $12,000,000 | (Jun 28, 2024)
Synthflow AI | $7,400,000 | (Jun 28, 2024)
Odaseva | $54,000,000 | (Jun 28, 2024)
KarmaCheck | $45,000,000 | (Jun 28, 2024)
Dodona Analytics | Undisclosed Amount | (Jun 28, 2024)
Ginossar Ventures | $13,000,000 | (Jun 28, 2024)